Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07220083

A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)

PODOMOUNT-pFSGS

This study is open to adults and adolescents with a kidney condition called focal segmental glomerulosclerosis (FSGS). The purpose of this study is to find out whether a medicine called BI 764198 helps people with FSGS.

Participants are put into 2 groups randomly, which means by chance. Every participant has an equal chance of being in each group. One group takes BI 764198 tablets, and the other group takes placebo tablets. Placebo tablets look like BI 764198 tablets but do not contain any medicine.

Participants take a tablet once a day for up to 2 years. All participants also continue their standard medication for FSGS.

Participants are in the study for up to 2 years. During this time, they visit the study site about every 3 months. Participants regularly collect urine samples. This is done to check their kidneys. The results are compared between the two groups to see whether the treatment works. The doctors also regularly check participants' health and take note of any unwanted effects.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Focal Segmental Glomerulosclerosis Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Glomerulonephritis Glomerulosclerosis, Focal Segmental Kidney Diseases Male Urogenital Diseases Nephritis Urogenital Diseases Urologic Diseases

Age range

12 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Terapia Renal Domiciliaria, Buenos Aires, Argentina

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female participants ≥12 years old on the day of signing informed consent/assent (Visit 1)
  • Weight of ≥40 kg at the screening visit (Visit 1)
  • Body mass index (BMI) of ≤40 kg/m² at the screening visit (Visit 1)
  • Participants with a diagnosis prior to the screening visit (Visit 1) of either:
  • Biopsy-confirmed primary focal segmental glomerulosclerosis (pFSGS) (based on Investigator's judgement) OR
  • Genetic focal segmental glomerulosclerosis (FSGS) resulting from a gain-of-function mutation in the transient receptor potential cation subfamily C member 6 (TRPC6) gene (based on historical genetic test)
  • Urine protein-creatinine ratio (UPCR) ≥1500 mg/g based on the mean of the spot urine sample and first morning void (FMV) urine sample (both assessed by central laboratory) at the screening visit (Visit 1)
  • Estimated glomerular filtration rate (eGFR)
  • For adult participants (≥18 years): ≥25 mL/min/1.73 m² (chronic kidney disease epidemiology collaboration (CKD-EPI) formula based on serum cystatin C) at the screening visit (Visit 1)
  • For adolescent participants (12 to <18 years): ≥25 mL/min/1.73 m² based on chronic kidney disease under 25 years (CKiD U25) formula using serum cystatin C at the screening visit (Visit 1) Further inclusion criteria apply.

Exclusion criteria

  • Known monogenic or syndromic causes of FSGS (with the exception of TRPC6 gain-of-function gene mutations)
  • Clinical or histologic evidence of secondary adaptive or toxic forms of FSGS (based on Investigator's judgement)
  • FSGS of undetermined cause (FSGS-UC) with a diagnosis prior to the screening visit (Visit 1) (based on Investigator's judgement)
  • A history of organ transplantation or planned organ transplantation during the course of the trial
  • Use of intravenous immunosuppressive agents (e.g. cyclophosphamide, rituximab, obinutuzumab) in the last 6 months prior to screening (Visit 1) Further exclusion criteria apply.

Treatment and study plan

BI 764198

Drug

BI 764198

Other names: Apecotrep

Placebo

Drug

Placebo matching BI 764198

Primary outcomes

  1. Relative change in 24-hour UPCR (measured in mg/g) from baseline to Week 104

    Time frame: Baseline and Week 104

    24-hour urinary protein-to-creatinine ratio (24-hr UPCR)

Secondary outcomes

  1. Key secondary endpoint: Absolute change in eGFRcys in mL/min/1.73m2 from baseline to Week 104

    Time frame: Baseline and Week 104

    Estimated glomerular filtration rate based on serum cystatin C (eGFRcys)

  2. Key secondary endpoint: Treatment response, defined as 24-hr UPCR <1000 mg/g at Week 104

    Time frame: At Week 104

    24-hour urinary protein-to-creatinine ratio (24-hr UPCR)

  3. Treatment response, defined as 24-hr UPCR <1000 mg/g and eGFRcys ≥85% vs. baseline at Week 104 and no treatment failure between randomisation and Week 104 (combined or multi-component endpoint)

    Time frame: At Week 104

    Treatment failure defined as:

    Use of rescue therapy (treatment escalation):

    • Worsening or severely active disease resulting in investigator-determined treatment failure and requiring rescue therapy (treatment escalation) during the trial. Treatment escalation includes initiation of a new medication or intensification of existing therapy, including an increase in the dose or target peak/trough level of selected concomitant medications (immunosuppressive therapies). Examples of intensification of immunosuppressive therapies used at screening, include:
    • calcineurin inhibitors (CNIs)
    • anti-metabolites (azathioprine, mycophenolate mofetil)
    • cytotoxic agents (cyclophosphamide, chlorambucil)
    • glucocorticoids, including escalation of prednisolone to ≥20 mg/day (oral or intravenous), or equivalent, for >14 days for treatment of kidney disease.

  4. Complete remission, defined as 24-hr UPCR <300 mg/g at Week 104

    Time frame: At Week 104

    24-hour urinary protein-to-creatinine ratio (24-hr UPCR)

  5. Change from baseline across disease-specific clinical outcome assessment (COA) NS-SIM-PRO at Week 104

    Time frame: Baseline and Week 104

    The nephrotic syndrome swelling impact measure (NS-SIM-PRO) has 23 items covering physical function (e.g. mobility), physical symptoms (e.g. fatigue, nausea), and essential function (e.g. vision) impacts identified as being important aspects of participants' experiences with nephrotic-syndrome related swelling.

    It is expected that all item responses will be combined to generate a single score representing overall swelling impact.

    The score ranges from 0 up to 4 (0 = never, 1 = almost never, 2 = sometimes, 3 = often, 4 = almost always). A lower score on any of the NS-SIM-PRO subscales indicate a better quality of life.

  6. Change from baseline across clinical outcome assessment (COA) KDQOL-36 at Week 104

    Time frame: Baseline and Week 104

    Kidney disease quality of life 36-item short form survey (KDQOL-36) assessing the health-related quality of life (HRQOL) in adult participants with kidney disease. It combines the generic SF-12 Health Survey with additional items specifically relevant to kidney disease.

    Key Components:

    • SF-12 Health Survey: Includes 12 items that measure physical and mental health, providing a broad overview of the patient's general health status.
    • Burden of Kidney Disease: This subscale (4 items) assesses how much kidney disease interferes with daily life and causes frustration.
    • Symptoms/Problems: This subscale (12 items) evaluates the frequency and severity of symptoms related to kidney disease, such as pain, fatigue, and sleep disturbances.
    • Effects of Kidney Disease: This subscale (8 items) measures the impact of kidney disease on daily activities and overall well-being.

    The score ranges from 0 up to 6 and a higher score on most of the KDQOL-36 subscales indicate a better quality of life.

Study contacts

Contact information is provided by the study sponsor or research team.

Boehringer Ingelheim

CONTACT

[email protected]

1-800-243-0127

Sponsors and collaborators

Lead sponsor

Boehringer Ingelheim

Industry

Registry information

Official study title

A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled Trial to Assess the Effects of Oral TRPC6 Inhibitor BI 764198 Taken Over a 104 Week Treatment Period in Adult and Adolescent Participants With Primary Focal Segmental Glomerulosclerosis (pFSGS) or Genetic FSGS Related to TRPC6 Gene Variants

Important dates

Study start
2026
Primary completion
2028
Study completion
2029
First posted
Oct 23, 2025
Registry last updated
Jul 23, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.